Drug Trial Radar · NCT07093008
Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Jun 13, 2025
Primary completion
Jul 16, 2025
Study completion Jul 22, 2025
Sponsor
- Lead sponsor
- AQILION ABIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.
Conditions
- Eosinophilic Esophagitis
Interventions
AQ280 CapsuleDrug
AQ280 administered orally in capsule formulation.
AQ280 Tablet for Oral SuspensionDrug
AQ280 administered orally in tablet for oral suspension formulation.
Placebo CapsuleDrug
Placebo administered orally in capsule formulation.
Placebo Tablet for Oral SuspensionDrug
Placebo administered orally in tablet for oral suspension formulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of AUC0-Inf for AQ280 Capsule vs Oral SuspensionTime frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Ratio of Cmax for AQ280 Capsule vs Oral SuspensionTime frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Maximum Observed Concentration (Cmax)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Time of the Maximum Observed Concentration (Tmax)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Apparent Terminal Elimination Half-life (t1/2)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Apparent Total Clearance (CL/F)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
- Apparent Volume of Distribution During the Terminal Phase (Vz/F)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Site
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.